{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:49:05Z","timestamp":1787237345100,"version":"build-2736575974"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,10,31]],"date-time":"2003-10-31T00:00:00Z","timestamp":1067558400000},"content-version":"vor","delay-in-days":2282,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[1997,8]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      van Barlingen HHJJ, van Beek A, Erkelens DW, de Bruin TWA (Department of Internal Medicine, Laboratory of Lipid Metabolism, University Hospital, Utrecht University, PO Box 85 500, 3508 GA Utrecht, The Netherlands). Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.\n                      <jats:italic>J Intern Med<\/jats:italic>\n                      1997;\n                      <jats:bold>242<\/jats:bold>\n                      : 125\u201329.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Heparin is a widely used antithrombotic drug. Besides its anticoagulant properties, it also has a marked influence on lipid metabolism, by decreasing serum lipolytic activity due to lipase depletion from vascular sites and stores. Especially in haemodialysis patients who receive heparin during every dialysis session, and in hypertriglyceridaemic patients, decreasing lipolytic activity can lead to the accumulation of triglyceride\u2010rich lipoproteins, which are atherogenic. Replacement of heparin by an antithrombotic drug with less lipase releasing activity might reduce this risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      We tested danaparoid, a new antithrombotic drug, and compared its ability to displace biotinylated heparan sulphate from lipoprotein lipase\n                      <jats:italic>in vitro<\/jats:italic>\n                      with heparin. Furthermore we compared the\n                      <jats:italic>in vivo<\/jats:italic>\n                      lipase releasing activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Danaparoid displaced significantly less biotinylated heparan sulphate from triglyceride\u2010rich lipoprotein\u2010lipoprotein lipase complexes\n                      <jats:italic>in vitro<\/jats:italic>\n                      than heparin. Intravenous injection of danaparoid released less than 20% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05) of the lipolytic activity released by an equivalent anticoagulant dose of heparin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Danaparoid is the drug of choice during the antithrombotic therapy of hypertriglyceridaemic or haemodialysis patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1046\/j.1365-2796.1997.00157.x","type":"journal-article","created":{"date-parts":[[2003,11,2]],"date-time":"2003-11-02T11:31:01Z","timestamp":1067772661000},"page":"125-129","source":"Crossref","is-referenced-by-count":5,"title":["Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans"],"prefix":"10.1111","volume":"242","author":[{"given":"H. H. J. J.","family":"van Barlingen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. W.","family":"Erkelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. W. A.","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,31]]},"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2796.1997.00157.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2796.1997.00157.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T16:04:37Z","timestamp":1698422677000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2796.1997.00157.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["10.1046\/j.1365-2796.1997.00157.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2796.1997.00157.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8]]}}}